Quotient Therapeutics Ltd is a privately held, early-stage company developing a novel genomics platform and therapeutics for diseases with a large unmet need.
Calling outstanding PhD Candidates who want to drive the future of biologic therapies...
...be among the very first in the world to use Qudos personal manufacturing as an oxidising Golgi-like production environment to precisely control glycosylation of next generation therapeutics.
We’re looking for a Research Scientist to undertake research projects which advance our understanding of the microbiome-gut-brain axis and its role in ageing. This role will be based in the group of Dr Aimee Parker in the Food, Microbiome and Health Programme at Quadram Institute.
San Diego, CA & Montpellier, FR – November 6, 2025 – Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, and Mabqi, a biotechnology company focused on the discovery and development of fully human antibodies, announced the formation of a strategic partnership. This collaboration will integrate Mabqi’s antibody discovery capabilities with Abzena’s development and manufacturing services, offering biopharma customers a more streamlined, end-to-end drug development solution.
Hosted by TABS Inc., Laura Devine Immigration, Frazier & Deeter and Seven Legal, this event is your chance to learn from experts about expanding your business to the US and how to secure funding for your venture. Join us for an informative panel discussion and workshop that will help you navigate the complexities of the American market. Don’t miss out on this opportunity to gain valuable insights and network with other founders looking to expand to the US market.
Who should attend?
In this panel webinar, we will discuss how artificial intelligence is advancing the prediction of molecular properties such as absorption, distribution, metabolism, and excretion (ADME). You will learn how Cresset’s AI-powered solution leverages machine learning techniques to efficiently identify promising drug candidates, reduce experimental workload, and accelerate candidate selection. We will cover practical strategies on how to use these AI models in your organization and how they can make drug discovery projects run more smoothly.
SoluLyse™ from Amsbio is a bacterial protein extraction reagent that provides a highly efficient yet gentle method for extracting soluble proteins from bacterial cells.
Based upon a proprietary non-ionic detergent formulation, with the SoluLyse™ reagent there is no need for time-consuming and cumbersome secondary treatment methods such as sonication or freeze thaw. The unique, mild SoluLyse™ formulation allows perforation of bacterial cell walls without denaturing proteins.
Based at Alderley Park, Medicines Discovery Catapult is a national Life Sciences service dedicated to turning drug discovery into commercial breakthroughs. We accelerate the development of science, and where there are areas of unmet patient need, we stimulate innovation.
About the company: TTP is an employee-owned technology and product development consultancy, with a 40-year track record of helping ambitious clients solve complex challenges and bring innovative, commercially successful solutions to market.
We invent, design, and manufacture impactful products and technologies across a wide range of industries – including healthcare, life science, energy, and communications – and at the intersection of engineering, physical science, and biology.
|